MEDICAL FACILITIES CORP (DR.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:DR - CA58457V5036 - Common Stock
15.33 CAD
-0.02 (-0.13%)
Overall DR gets a fundamental rating of 7 out of 10. We evaluated DR against 14 industry peers in the Health Care Providers & Services industry. Both the health and profitability get an excellent rating, making DR a very profitable company, without any liquidiy or solvency issues. DR is cheap, but on the other hand it scores bad on growth. This makes DR very considerable for value investing!
1. Profitability
1.1 Basic Checks
In the past year DR was profitable.
In the past year DR had a positive cash flow from operations.
Of the past 5 years DR 4 years were profitable.
Each year in the past 5 years DR had a positive operating cash flow.
1.2 Ratios
DR has a Return On Assets of 30.18%. This is amongst the best in the industry. DR outperforms 92.86% of its industry peers.
With an excellent Return On Equity value of 94.43%, DR belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
The Return On Invested Capital of DR (15.42%) is better than 92.86% of its industry peers.
The Average Return On Invested Capital over the past 3 years for DR is significantly above the industry average of 7.27%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.18% | ||
| ROE | 94.43% | ||
| ROIC | 15.42% |
ROA(3y)8.42%
ROA(5y)6.13%
ROE(3y)25.39%
ROE(5y)18.93%
ROIC(3y)16.37%
ROIC(5y)14.6%
1.3 Margins
The Profit Margin of DR (31.60%) is better than 92.86% of its industry peers.
DR's Profit Margin has improved in the last couple of years.
The Operating Margin of DR (15.59%) is better than 100.00% of its industry peers.
DR's Operating Margin has been stable in the last couple of years.
Looking at the Gross Margin, with a value of 63.75%, DR belongs to the top of the industry, outperforming 85.71% of the companies in the same industry.
DR's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.59% | ||
| PM (TTM) | 31.6% | ||
| GM | 63.75% |
OM growth 3Y-0.97%
OM growth 5Y-1.3%
PM growth 3Y78.64%
PM growth 5Y55.2%
GM growth 3Y-0.53%
GM growth 5Y-0.42%
2. Health
2.1 Basic Checks
DR has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, DR has less shares outstanding
The number of shares outstanding for DR has been reduced compared to 5 years ago.
The debt/assets ratio for DR has been reduced compared to a year ago.
2.2 Solvency
DR has an Altman-Z score of 1.35. This is a bad value and indicates that DR is not financially healthy and even has some risk of bankruptcy.
DR has a Altman-Z score of 1.35. This is in the better half of the industry: DR outperforms 71.43% of its industry peers.
DR has a debt to FCF ratio of 2.05. This is a good value and a sign of high solvency as DR would need 2.05 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 2.05, DR belongs to the top of the industry, outperforming 92.86% of the companies in the same industry.
A Debt/Equity ratio of 1.02 is on the high side and indicates that DR has dependencies on debt financing.
The Debt to Equity ratio of DR (1.02) is comparable to the rest of the industry.
Even though the debt/equity ratio score it not favorable for DR, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.02 | ||
| Debt/FCF | 2.05 | ||
| Altman-Z | 1.35 |
ROIC/WACC1.81
WACC8.5%
2.3 Liquidity
A Current Ratio of 1.79 indicates that DR should not have too much problems paying its short term obligations.
DR has a better Current ratio (1.79) than 100.00% of its industry peers.
DR has a Quick Ratio of 1.67. This is a normal value and indicates that DR is financially healthy and should not expect problems in meeting its short term obligations.
DR has a Quick ratio of 1.67. This is amongst the best in the industry. DR outperforms 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.79 | ||
| Quick Ratio | 1.67 |
3. Growth
3.1 Past
DR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.81%, which is quite impressive.
DR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -41.68%.
Measured over the past years, DR shows a decrease in Revenue. The Revenue has been decreasing by -3.59% on average per year.
EPS 1Y (TTM)60.81%
EPS 3Y10.86%
EPS 5Y0%
EPS Q2Q%-23.33%
Revenue 1Y (TTM)-41.68%
Revenue growth 3Y-5.96%
Revenue growth 5Y-3.59%
Sales Q2Q%-20.29%
3.2 Future
DR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.76% yearly.
DR is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -7.10% yearly.
EPS Next Y34.23%
EPS Next 2Y14.43%
EPS Next 3Y10.76%
EPS Next 5YN/A
Revenue Next Year-20.98%
Revenue Next 2Y-10.85%
Revenue Next 3Y-7.1%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 9.40, the valuation of DR can be described as very reasonable.
DR's Price/Earnings ratio is rather cheap when compared to the industry. DR is cheaper than 92.86% of the companies in the same industry.
When comparing the Price/Earnings ratio of DR to the average of the S&P500 Index (26.57), we can say DR is valued rather cheaply.
A Price/Forward Earnings ratio of 9.10 indicates a reasonable valuation of DR.
DR's Price/Forward Earnings ratio is rather cheap when compared to the industry. DR is cheaper than 100.00% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 24.04. DR is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.4 | ||
| Fwd PE | 9.1 |
4.2 Price Multiples
100.00% of the companies in the same industry are more expensive than DR, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of DR indicates a rather cheap valuation: DR is cheaper than 92.86% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.14 | ||
| EV/EBITDA | 4.48 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
DR has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)0.27
PEG (5Y)N/A
EPS Next 2Y14.43%
EPS Next 3Y10.76%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 2.35%, DR has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 1.17, DR pays a better dividend. On top of this DR pays more dividend than 85.71% of the companies listed in the same industry.
DR's Dividend Yield is a higher than the S&P500 average which is at 1.88.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.35% |
5.2 History
The dividend of DR decreases each year by -19.91%.
DR has been paying a dividend for at least 10 years, so it has a reliable track record.
DR has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)-19.91%
Div Incr Years1
Div Non Decr Years4
5.3 Sustainability
DR pays out 6.72% of its income as dividend. This is a sustainable payout ratio.
DP6.72%
EPS Next 2Y14.43%
EPS Next 3Y10.76%
TSX:DR (12/24/2025, 7:00:00 PM)
15.33
-0.02 (-0.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.98%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap276.71M
Revenue(TTM)257.36M
Net Income(TTM)81.33M
Analysts42.22
Price Target16.58 (8.15%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.35% |
Yearly Dividend0.35
Dividend Growth(5Y)-19.91%
DP6.72%
Div Incr Years1
Div Non Decr Years4
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.6%
Min EPS beat(2)-7.54%
Max EPS beat(2)6.33%
EPS beat(4)2
Avg EPS beat(4)3.38%
Min EPS beat(4)-24.98%
Max EPS beat(4)39.71%
EPS beat(8)3
Avg EPS beat(8)-25.78%
EPS beat(12)5
Avg EPS beat(12)32.86%
EPS beat(16)7
Avg EPS beat(16)-103.27%
Revenue beat(2)1
Avg Revenue beat(2)-1.3%
Min Revenue beat(2)-4.5%
Max Revenue beat(2)1.91%
Revenue beat(4)1
Avg Revenue beat(4)-6.39%
Min Revenue beat(4)-18.84%
Max Revenue beat(4)1.91%
Revenue beat(8)3
Avg Revenue beat(8)-3.49%
Revenue beat(12)4
Avg Revenue beat(12)-2.43%
Revenue beat(16)5
Avg Revenue beat(16)-2.23%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)15.63%
EPS NY rev (1m)1.24%
EPS NY rev (3m)1.24%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.91%
Revenue NY rev (1m)1.27%
Revenue NY rev (3m)1.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.4 | ||
| Fwd PE | 9.1 | ||
| P/S | 0.79 | ||
| P/FCF | 4.14 | ||
| P/OCF | 3.81 | ||
| P/B | 2.35 | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.48 |
EPS(TTM)1.63
EY10.63%
EPS(NY)1.68
Fwd EY10.99%
FCF(TTM)3.7
FCFY24.17%
OCF(TTM)4.03
OCFY26.26%
SpS19.51
BVpS6.53
TBVpS-0.86
PEG (NY)0.27
PEG (5Y)N/A
Graham Number15.47
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.18% | ||
| ROE | 94.43% | ||
| ROCE | 18.66% | ||
| ROIC | 15.42% | ||
| ROICexc | 19.71% | ||
| ROICexgc | 46.81% | ||
| OM | 15.59% | ||
| PM (TTM) | 31.6% | ||
| GM | 63.75% | ||
| FCFM | 18.99% |
ROA(3y)8.42%
ROA(5y)6.13%
ROE(3y)25.39%
ROE(5y)18.93%
ROIC(3y)16.37%
ROIC(5y)14.6%
ROICexc(3y)21.7%
ROICexc(5y)18.79%
ROICexgc(3y)53.59%
ROICexgc(5y)43.79%
ROCE(3y)19.81%
ROCE(5y)17.76%
ROICexgc growth 3Y35.06%
ROICexgc growth 5Y23.36%
ROICexc growth 3Y18.42%
ROICexc growth 5Y13.1%
OM growth 3Y-0.97%
OM growth 5Y-1.3%
PM growth 3Y78.64%
PM growth 5Y55.2%
GM growth 3Y-0.53%
GM growth 5Y-0.42%
F-Score6
Asset Turnover0.95
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.02 | ||
| Debt/FCF | 2.05 | ||
| Debt/EBITDA | 1.54 | ||
| Cap/Depr | 25.03% | ||
| Cap/Sales | 1.64% | ||
| Interest Coverage | 7.65 | ||
| Cash Conversion | 93.1% | ||
| Profit Quality | 60.09% | ||
| Current Ratio | 1.79 | ||
| Quick Ratio | 1.67 | ||
| Altman-Z | 1.35 |
F-Score6
WACC8.5%
ROIC/WACC1.81
Cap/Depr(3y)47.79%
Cap/Depr(5y)40.36%
Cap/Sales(3y)2.81%
Cap/Sales(5y)2.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.81%
EPS 3Y10.86%
EPS 5Y0%
EPS Q2Q%-23.33%
EPS Next Y34.23%
EPS Next 2Y14.43%
EPS Next 3Y10.76%
EPS Next 5YN/A
Revenue 1Y (TTM)-41.68%
Revenue growth 3Y-5.96%
Revenue growth 5Y-3.59%
Sales Q2Q%-20.29%
Revenue Next Year-20.98%
Revenue Next 2Y-10.85%
Revenue Next 3Y-7.1%
Revenue Next 5YN/A
EBIT growth 1Y-46.1%
EBIT growth 3Y-6.86%
EBIT growth 5Y-4.85%
EBIT Next Year5.03%
EBIT Next 3Y2.4%
EBIT Next 5YN/A
FCF growth 1Y-6.31%
FCF growth 3Y4.28%
FCF growth 5Y3.38%
OCF growth 1Y-24.65%
OCF growth 3Y3.26%
OCF growth 5Y1.55%
MEDICAL FACILITIES CORP / DR.CA FAQ
What is the fundamental rating for DR stock?
ChartMill assigns a fundamental rating of 7 / 10 to DR.CA.
What is the valuation status for DR stock?
ChartMill assigns a valuation rating of 9 / 10 to MEDICAL FACILITIES CORP (DR.CA). This can be considered as Undervalued.
Can you provide the profitability details for MEDICAL FACILITIES CORP?
MEDICAL FACILITIES CORP (DR.CA) has a profitability rating of 8 / 10.
Can you provide the PE and PB ratios for DR stock?
The Price/Earnings (PE) ratio for MEDICAL FACILITIES CORP (DR.CA) is 9.4 and the Price/Book (PB) ratio is 2.35.
Can you provide the dividend sustainability for DR stock?
The dividend rating of MEDICAL FACILITIES CORP (DR.CA) is 5 / 10 and the dividend payout ratio is 6.72%.